BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment

BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 million based on milestones. Alesta Therapeutic's lead drug is a potential treatment for hypophosphatasia (HPP).

CNBC • Aug 19, 2026

BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment

BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline.

Zacks Investment Research • Aug 19, 2026

BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline

BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones Alesta to spin out all non-ALE1 assets to a new entity and Alesta employees to transfer to the spinout entity prior to close ALE1 has significant potential to help BioMarin expand into larger rare disease markets with a medicine intended to address a high unmet need for patients and offers strong strategic fit for the company SAN RAFAEL, Calif., Aug. 18, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1.

PRNewsWire • Aug 18, 2026

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

Here is how BioMarin Pharmaceutical (BMRN) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks Investment Research • Aug 14, 2026

5 Undervalued Price-to-Book Stocks Worth Buying in August

BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.

Zacks Investment Research • Aug 13, 2026

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth

BioMarin Pharmaceutical NASDAQ: BMRN outlined its growth strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord discussion with Chief Financial Officer Brian Mueller.

MarketBeat • Aug 12, 2026

BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Seeking Alpha • Aug 12, 2026

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Aug 12, 2026

Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High?

The mean of analysts' price targets for BioMarin (BMRN) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Aug 12, 2026

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Aug 12, 2026